Knowledge Center · Peptides

BPC-157

Research peptideNot FDA-approvedPreclinical evidenceBanned in sport (WADA)

BPC-157 is a synthetic peptide studied primarily in animals for its proposed effects on tissue repair. Interest is high, but the evidence base is largely preclinical — meaningful human clinical trial data is limited.

On this pageOverviewWhat is it?MechanismEvidenceApplicationsWhat we knowWhat we don't knowRisksDiscuss with a providerFAQReferences

Overview

BPC-157 (“Body Protection Compound-157”) is a synthetic chain of 15 amino acids derived from a partial sequence of a protective protein identified in human gastric juice. In animal studies it has been associated with accelerated healing of tendon, ligament, muscle, and gastrointestinal tissue. Popularity has outpaced the evidence, and it is important to separate the two.

What is it?

BPC-157 is a stable, synthetically produced peptide. It is sold as a “research chemical,” not as an approved medication, and research-supply product is not manufactured to pharmaceutical standards — raising real questions about purity, identity, and sterility.

Mechanism of Action

The mechanism is not fully understood. The most-cited proposed pathways, based on laboratory and animal work, include:

  • Angiogenesis — promotion of new blood-vessel formation, possibly via the VEGF pathway, which could support tissue repair.
  • Nitric oxide (NO) system modulation — interaction with NO pathways that influence blood flow and cytoprotection.
  • Growth-factor and fibroblast effects — influence on cells involved in tendon and ligament healing in vitro.

These are mechanistic hypotheses supported mainly by preclinical models — not established mechanisms confirmed in humans.

Current Scientific Evidence

The honest summary: the evidence is predominantly preclinical.

Evidence typeStatus
Animal (rodent) studiesNumerous; suggest accelerated soft-tissue and GI healing. A large share originate from a single research group, which limits independent replication.
In-vitro (cell) studiesSupport proposed angiogenic and fibroblast effects.
Human clinical trialsVery limited. There is not yet robust, large-scale, peer-reviewed human trial evidence establishing efficacy or long-term safety.

Potential Clinical Applications (under investigation)

Areas explored in preclinical research — none of which constitute proven human uses — include musculoskeletal injury recovery (tendon/ligament/muscle) and gastrointestinal models. These are research directions, not established treatments.

What We Know

  • It is a well-characterized synthetic peptide with a consistent structure.
  • Animal data fairly consistently shows pro-healing signals across several tissue types.
  • It is not FDA-approved and is prohibited in sport under WADA.

What We Don't Know

  • Whether the animal findings translate to meaningful benefit in humans.
  • Optimal dose, route, and duration in humans.
  • Long-term safety, including any effects on abnormal tissue or vasculature.
  • The purity and identity of any specific research-grade product.

Potential Risks & Considerations

  • Limited human safety data — long-term effects are not established.
  • Product quality — research-supply peptides are not pharmaceutical-grade; contamination and mislabeling are real risks.
  • Theoretical concern — because angiogenesis supports the growth of all tissue, stimulating blood-vessel formation in the presence of abnormal tissue is not well understood.
  • Sport eligibility — prohibited under WADA.
  • Legal status varies by jurisdiction.

Who May Wish to Discuss It With Their Provider

Anyone considering BPC-157 should do so only in conversation with a qualified, licensed provider who can weigh their individual history, current medications, goals, and the limits of the evidence — and advise on legality and sourcing. This page is not a recommendation to use BPC-157.

Frequently Asked Questions

Is BPC-157 FDA approved?

No. It is not an approved drug and is sold as a research chemical. Legal status varies by jurisdiction.

Is there human evidence?

The large majority of research is preclinical. Robust human clinical trial data is very limited.

Is it banned in sport?

Yes — it is on the WADA Prohibited List, so it is prohibited for athletes subject to anti-doping rules.

Have questions about your own situation?

If you'd like help applying this information to your own health, schedule a consultation with the Bearing team.

Request a Consultation

Scientific References

  • Body of preclinical BPC-157 research led by Sikiric P. and colleagues (University of Zagreb). Search PubMed: “BPC 157” for primary literature.
  • World Anti-Doping Agency (WADA) Prohibited List — BPC-157 listing.
  • Reviews of peptide therapeutics in musculoskeletal and gastrointestinal research (preclinical).

References are provided for further reading. Bearing summarizes the literature conservatively and updates pages as evidence evolves.

Related

Peptides: TB-500 · GHK-Cu · Tools: Peptide Reconstitution Calculator

Educational disclaimer. This page is for general education and is not medical advice. It does not diagnose, treat, or recommend any substance. Many peptides are not FDA-approved; legal status varies and some are prohibited in sport. Discuss any decision with a licensed provider.